New research indicates proportion of young women who have never been screened for cervical cancer more than doubled since 2005
Developed by a British firm, the test will be available as a $29 add-on to pricier genetic profiling assays
Clinical laboratories may soon be able to use a simplified LDL cholesterol calculation
From – Diagnostic Testing & Emerging Technologies
Child–parent hypercholesterolemia (FH) screening is a practical and effective way of conducting population-based screening to identify the…
From – Diagnostic Testing & Emerging Technologies
With Theranos’ recent announcement of its transition away from laboratory operations toward technology development…
...
From – Diagnostic Testing & Emerging Technologies
Reanalysis of clinical exome data at a two- to three-year interval could result in an incremental 10 percent diagnostic yield…
From – Diagnostic Testing & Emerging Technologies
Patients increasingly prefer to receive laboratory test results via password-protected websites and portals, according to…
...
...
...
From – Diagnostic Testing & Emerging Technologies
Mass spectrometry (MS) is rapidly transitioning from specialized clinical testing—drugs of abuse confirmations, newborn screening, and steroid analysis—to being broadly applied throughout…
...